Green Planet Bioengineering (GPLB) Stock Price, News & Analysis

Company Overview

Green Planet Bioengineering, Inc. (OTCMKTS:GPLB) is a biotechnology company specializing in the development of advanced tissue-engineering solutions for research and therapeutic applications. The company focuses on creating three-dimensional, biomimetic scaffolds that support cell growth and differentiation, enabling more accurate in vitro models for drug discovery, regenerative medicine, and personalized healthcare. Utilizing a combination of synthetic polymers and naturally derived biomaterials, Green Planet aims to bridge the gap between traditional two-dimensional cell cultures and complex biological systems.

At the core of Green Planet’s offerings are its proprietary scaffold platforms, which include collagen-based matrices and hyaluronic acid composites designed to emulate the extracellular environment of human tissues. These products are tailored to a range of cell types, from stem cells to primary cells, and are compatible with high-throughput screening workflows. In addition to off-the-shelf scaffold kits, Green Planet provides custom contract development services, working closely with pharmaceutical firms, academic institutions, and contract research organizations to design models for oncology, neurology, and cardiology studies.

Founded in 2014 by a team of biomedical engineers and life-science entrepreneurs, Green Planet has expanded its operations across North America, Europe, and Asia. The company’s research and manufacturing facilities include a primary headquarters in Massachusetts, a production laboratory in the Netherlands, and a joint-venture centre in Singapore. Over the past decade, Green Planet has forged strategic partnerships with leading universities and biopharma companies, securing collaborative grants to advance three-dimensional tissue constructs and organoid technologies.

Green Planet’s leadership team brings together seasoned executives and scientific experts. Chief Executive Officer Dr. Jennifer Chen has over 20 years of experience in regenerative medicine, while President and Chief Operating Officer Dr. Samuel Ng co-founded the company after a tenure in academic tissue-engineering research. Chief Financial Officer Michael Lee oversees capital strategy and corporate finance, supported by a board of directors that includes industry veterans in biomanufacturing and pharmaceutical development. Together, this team guides Green Planet’s mission to deliver next-generation bioengineering solutions to the global life-sciences community.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.04 to $0.20
• 52-Week Range: $0.02 to $0.70
• Volume: N/A
• Average Volume: 3,055 shs
• Market Capitalization: $800.40 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GPLB Stock Analysis - Frequently Asked Questions

How have GPLB shares performed this year?

Green Planet Bioengineering's stock was trading at $0.54 at the beginning of the year. Since then, GPLB stock has decreased by 92.6% and is now trading at $0.04.

How do I buy shares of Green Planet Bioengineering?

Shares of GPLB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Green Planet Bioengineering own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Green Planet Bioengineering investors own include Warner Music Group (WMG), Verizon Communications (VZ) and Evonik Industries (EVK).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Finance
• Industry: Financial Conglomerates
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GPLB
• CIK: 1392449
• Web: www.greenplanetbio.com.cn
• Phone: (786) 279-2900
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 20,010,000
• Free Float: N/A
• Market Cap: $800.40 thousand
• Optionable: Not Optionable
• Beta: 3.07